Development and commercialization of drugs for rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Chiesi SAS
B
Development and marketing of pharmaceuticals in respiratory, neonatology, transplantation, and rare diseases.
Servier
A
Development and marketing of pharmaceuticals in the fields of oncology, cardiometabolism, and neurology.
Initiatives identified among leaders
Contribuer à améliorer le taux de survie des enfants atteints de cancer
“LES LABORATOIRES SERVIER INDUSTRIE contribue à amé...” - ServierLancement d'un plan d'amélioration global
“Chiesi SAS lance un plan d'amélioration global pou...” - Chiesi SASPromotion de l'égalité femmes-hommes
“Genethon promeut l'égalité femmes-hommes, avec 67%...” - Genethon60% of similar organizations communicate on CSR issues
+1435 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports